Drug Type Synthetic peptide |
Synonyms G alpha-13 inhibitor (University of Illinois), M-3MP6, M3mP6 |
Target |
Action inhibitors |
Mechanism GNA13 inhibitors(G protein subunit alpha 13 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Diseases | Preclinical | United States | 03 May 2023 | |
| Respiratory Distress Syndrome, Acute | Preclinical | United States | 03 May 2023 | |
| Myocardial Ischemia | Preclinical | United States | - | |
| Reperfusion Injury | Preclinical | United States | - | |
| Thrombosis | Preclinical | United States | - |






